31 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
, as we continued our commercialization efforts.
For the fourth quarter and year ended December 31, 2023, our research and development (R&D) expenses were … and associated staff costs, increases related to consumables and facilities costs, and decreased R&D tax credits due to us no longer qualifying
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
for sustainable growth David Berman, Head of R&D Delivering on our promise Bahija Jallal, CEO Q&A Session 3 4Q23 & FY23 financial results Brian Di Donato, CFO … of 8% Collaboration revenues 2.2 2.6 10.7 R&D expense 43.2 45.6 163.5 SG&A expenses 35.5 41.4 144.5 Net income/(loss) for the period 0.9 (19.7) (55.3
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
forward and utilization against future operating profits.
As a company that carries out extensive research and development, or R&D, activities, we … benefit from the U.K. R&D tax relief programs, historically being the Small and Medium-sized Enterprises R&D tax relief program, or SME Program
8-K
IMCR
Immunocore Holdings plc
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
and development (“R&D”) expenses and selling, general and administrative (“SG&A”) expenses will increase when compared to such expenses for the third quarter … of 2023. The increases in R&D expenses and SG&A expenses described do not include unrealized foreign exchange losses on the translation of monetary
6-K
EX-99.2
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
.
Amendments to the U.K. R&D tax credit regime have recently been enacted, proposed or are under consultation. These amendments (amongst other things) (i … and may (unless limited exceptions apply) introduce restrictions on the tax relief that can be claimed for expenditure incurred on sub-contracted R&D activities
6-K
EX-99.1
cee1uep mzjn5pk1
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.4
48kci
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
q0b7xd6xm
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
8nsqi 0dom
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
3o8qc3u
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
lw7 ikgnlnjkxa
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
7rp65qq09f
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
utrto
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.4
6ytbk4 e0
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
4rl4qo5ojbtjv
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
apey8f 47iyi0h37
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
kzuhyu5 bd
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
ta45q7x
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.3
az3r76qjg1i5iwg5l74a
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am